---
layout: post
title:  "TRK抑制剂综述"
date:   2018-12-11 21:00:00 +0800
tags: JMC cancer review
excerpt:  原文标题：Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors： Development and Clinical Application
---

##### 原文标题：[Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application][artical_url]

### Abstract
> The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed,
  with the majority of cases exhibiting a TRK genomic rearrangement.

自伊马替尼的发现和发展以来，人们正在极力追求以激酶为导向的精准药物。每年大约有2万起原肌球蛋白受体激酶（TRK）癌症患者被诊断出来，这些患者主要表现为TRK基因组重排。（TRK激酶抑制剂很重要）

> In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: 
(1) the biological background and significance of the TRK kinase family,
(2) a compilation of known TRK inhibitors and analysis of their cocrystal structures,
(3) an overview of TRK clinical trials, and
(4) future perspectives for drug discovery and development of TRK inhibitors.

在这篇展望中（这里Perspective为啥大写P？），我们在以下方面讨论了当前TRK精准药物的研究和临床应用：  
（1）TRK激酶家族的生物背景和意义  
（2）已知的TRK抑制剂和他们的共晶结构  
（3）TRK的临床应用  
（4）TRK抑制剂的展望和药物发现发展

### Introduction

> The tropomyosin receptor kinase (TRK) family of enzymes are transmembrane receptor tyrosine kinases (RTKs) that regulate synaptic strength and plasticity in the mammalian nervous system. In this role, the TRK family regulates cell differentiation, proliferation, survival, and pain.

1. transmembrane n.跨膜
2. mammalian n.突触
3. plasticity n.可塑性
4. mammalian n.哺乳动物

TRK家族是一类跨膜受体酪氨酸激酶，它主要用来在哺乳动物神经系统上调控突触强度和韧性。在这方面，TRK家族调控细胞分化、增殖、生存和疼痛。

> There are three members of the TRK family: TRKA (encoded by NTRK1 gene), TRKB (NTRK2), and TRKC (NTRK3), which have all been implicated in the initiation and progression of malignancies. Similar to the BCR-ABL gene fusion product that drives chronic myelogenous leukemia (CML), NTRK rearrangements and fusion gene products have been observed in numerous tumor types, which has been comprehensively reviewed by Vaishnavi et al. and Amatu et al. Unlike CML, however, the incidence of NTRK fusion genes in each specific tumor type overall is rare. This generates profound difficulties for patient identification and adequate recruitment for clinical trials.

1. implicated v.牵连
2. malignancies n.恶性肿瘤
3. fusion n.融合
4. chronic myelogenous leukemia 慢性粒细胞白血病

TRK家族有三个成员：TRKA、TRKB、TRKC，这些都涉及到恶性肿瘤的发生和发展。和BCR-ABL融合基因产物类似，TRK驱动慢性粒细胞白血病(CML)、NTRK重排、融合基因产物等，这些在神经肿瘤细胞中得到验证，并且已经由V和A等综述过了。然而不像CML，NTRK融合基因在各种类型的肿瘤细胞中都很少见。这给病人的诊断和需求足够的病人产生了极大的困难。

```markdown
融合基因  
融合基因（英语：Fusion gene）是指两个基因的全部或一部分的序列相互融合为一个新的基因的过程。  
其有可能是染色体易位、中间缺失或染色体倒置所致的结果。
```

> For instance, NTRK2 gene fusions have been identified in 0.2% of lung adenocarcinoma, which represents approximately 184 patients of 92 138 diagnosed in 2010 in the USA. On the other end of the spectrum, NTRK3 fusion genes have been identified in virtually all secretory breast carcinomas and of mammary analogue secretory carcinomas (MASC), an extremely rare tumor of the salivary (in general, of the parotid) gland.

1. lung adenocarcinoma 肺腺癌
2. spectrum n.范围
3. secretory breast carcinomas 分泌性乳腺癌
4. mammary analogue secretory carcinomas 乳腺类似物分泌癌
5. salivary n.唾液
6. parotid n.耳下腺
7. gland n.腺

比如，NTRK2融合基因在0.2%的肺腺癌患者中得到确证，在2010的美国，大概每92138人就有184个人诊断出肺腺癌。另外，NTRK3融合基因主要在所有的分泌性乳腺癌和乳腺类似物分泌癌(MASC)中确证。乳腺类似物分泌癌是唾液腺（通常是耳下腺）中十分罕见的肿瘤。

> In fact, the defining characteristic of MASC, when compared to other salivary carcinomas, is an NTRK gene fusion. In addition, NTRK fusions are found in about 50% of pediatric diffuse intrinsic pontine glioma and non-brainstem glioblastoma. In major cancer subgroups, NTRK fusions occur in 3.3% of lung cancers, 2.2% of colorectal cancers, 16.7% of thyroid cancers, 2.5% of glioblastomas, and 7.1% of pediatric gliomas. Finally, similar to the receptor tyrosine kinase RET (rearranged during transfection), NTRK fusions (particularly ETV6-NTRK3) are common in post-Chernobyl radiation-induced papillary thyroid carcinomas. Thus, targeting TRK oncogenes is an attractive therapeutic approach for a diverse, frequently rare set of cancers.

1. salivary carcinomas 唾液癌
2. pediatric diffuse intrinsic pontine glioma 小儿弥漫性脑桥脑胶质瘤
3. non-brainstem glioblastoma 非脑干胶质母细胞瘤
4. colorectal cancer 结直肠癌
5. thyroid cancers 甲状腺癌
6. Chernobyl radiation 切尔诺贝利辐射
7. papillary thyroid carcinomas 乳头状甲状腺癌

实际上，和唾液哎比较，MASC的特征就是NTRK融合基因。另外，NTRK融合基因可以在50%的小儿弥漫性脑桥脑胶质瘤和非脑干胶质母细胞瘤中发现。在主要的癌症中，NTRK基因融合也出现在3.3%的肺癌、2.2%的结直肠癌、16.7%%的甲状腺癌和7.1%的小儿神经胶质瘤中。而且，和酪氨酸激酶RET（在转染过程中重排）类似，NTRK融合（特别是ETV6-NTRK3)在切尔诺贝利辐射诱导的乳头状甲状腺癌中很常见。因此，以TRK癌基因为靶点是一种有吸引力的对多种，少见癌症的治疗方法。（针对TRK就是抑制基因融合，就可以抑制肿瘤）

> The primary method to target TRK oncogenes is the use of small molecule kinase inhibitors. Because gene fusion products are the major oncogenes observed, other targeting strategies, such as antibody therapy, will not be effective since transmembrane tyrosine kinase fusions frequently lack an extracellular domain. In this case, the fusion proteins are only susceptible to small molecule inhibition.

1. susceptible adj.易感

主要针对TRK癌基因的方法是小分子激酶抑制剂。因为癌基因主要是基因融合产物，其他的靶点策略，比如抗体治疗，由于跨膜酪氨酸激酶融合一般缺少胞外域，所有通常没有什么效果。因此，融合蛋白只对小分子抑制剂敏感（小分子比抗体好） 

> In general, small molecules are designed to target the adenosine triphosphate (ATP) binding site of TRK to block catalytic activity. This is based on the principle that protein kinases catalyze a phosphoryl transfer to a downstream substrate and only have micromolar affinity for ATP. Since turnover is rapid and kinase affinity for ATP is weak, small molecules can effectively bind and inhibit TRK despite a high endogenous concentration of ATP. Because of the druggability of the TRK enzyme class, a number of attempts to target TRKs have been completed. In this Perspective, we discuss current development and clinical application of TRK-targeted cancer therapy.

1. phosphoryl transfer 磷酰基转移

一般来说，小分子设计来进入TRK的ATP结合位点去阻止催化活性。这是基于蛋白激酶催化磷酰基转移下游物质，所以对ATP的结合是微摩尔级别。因为ATP转移是快速的，所以激酶对ATP的结合很弱，小分子可以很高效的抑制TRK尽管内源ATP的浓度十分高。正是由于TRK类酶的高度可成药性，许多以TRK为靶点的药物已经完成了。在这片展望中，我们讨论了当前TRK为靶点的癌症治疗的发展和临床应用。

[artical_url]: https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01092